Cholera Vaccines Market Report by Vaccine Type (Whole Cell V. Cholerae O1 with Recombinant B-Subunit, Killed Oral O1 and O139), Product (Dukoral, Shanchol, Vaxchora, Euvichol and Euvichol-Plus, and Others), End User (Hospitals and Clinics, Research and Ac

Cholera Vaccines Market Report by Vaccine Type (Whole Cell V. Cholerae O1 with Recombinant B-Subunit, Killed Oral O1 and O139), Product (Dukoral, Shanchol, Vaxchora, Euvichol and Euvichol-Plus, and Others), End User (Hospitals and Clinics, Research and Academic Laboratories, and Others), and Region 2024-2032

The global cholera vaccines market size reached US$ 5.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.0 Million by 2032, exhibiting a growth rate (CAGR) of 10% during 2024-2032. The increasing public awareness of cholera prevention, robust government initiatives and international collaboration, continual advancements in vaccine technology, the surge in travel and trade, ongoing research and development activities, and the emphasis on global health are some of the factors fueling the market growth.

Cholera vaccines are medical interventions designed to provide protection against cholera, a bacterial infection that causes diarrhea and can lead to dehydration and even death. They are developed using a combination of inactivated or attenuated Vibrio cholerae bacteria, the causative agent of cholera. The process involves growing large quantities of the bacteria, rendering them non-virulent, and then formulating them into vaccines. The advantages of cholera vaccines are significant, such as they offer a proactive approach to preventing cholera outbreaks, particularly in regions with inadequate sanitation and water supplies. By bolstering the immune system's ability to recognize and fight the cholera bacteria, these vaccines can reduce the severity and duration of the illness. Moreover, they contribute to reducing the transmission of cholera within communities and across borders. Two main types of cholera vaccines include oral and injectable.

The global cholera vaccines market is influenced by the increasing awareness about cholera prevention and the importance of vaccination, especially in regions prone to outbreaks. Additionally, government initiatives and international organizations' efforts to control cholera's spread through vaccination campaigns play a pivotal role in market expansion. Moreover, advancements in vaccine technology, resulting in the development of more efficient and cost-effective vaccines, bolster market growth. Furthermore, the rising frequency of travel and international trade fosters the need for cholera vaccination, as travelers can potentially carry the disease across borders, which, in turn, is supporting the market growth. Besides this, ongoing research and development (R&D) activities aimed at enhancing vaccine efficacy and safety are contributing to the market growth.

Cholera Vaccines Market Trends/Drivers:
Increasing awareness and cholera prevention

The global cholera vaccines market experiences a significant impetus from the increasing awareness surrounding cholera prevention and the crucial role of vaccination. As communities become more informed about the devastating impact of cholera outbreaks, the demand for effective preventive measures, including vaccination, rises. This heightened awareness is often driven by public health campaigns, educational initiatives, and media coverage that highlight the consequences of cholera and the importance of vaccination in curbing its spread. This driver not only stimulates individual and community-level interest in vaccination but also encourages governments, healthcare organizations, and international bodies to allocate resources towards vaccination campaigns, propelling market growth.

Government initiatives and international efforts

Government initiatives and collaborative efforts by international organizations contribute significantly to the expansion of the global cholera vaccines market. Governments of cholera-prone regions recognize the socio-economic burden posed by cholera and prioritize vaccination programs as a crucial preventive strategy. Moreover, international organizations like the World Health Organization (WHO) and UNICEF engage in partnerships with governments, providing technical expertise, funding, and vaccine supply to support vaccination campaigns. This coordinated approach not only ensures vaccine accessibility in resource-constrained regions but also fosters a conducive environment for market growth by creating a steady demand for cholera vaccines.

Advancements in vaccine technology

Advancements in vaccine technology play a pivotal role in propelling the global cholera vaccines market forward. As research and development efforts focus on improving vaccine efficacy, safety, and production processes, newer and more effective cholera vaccines are introduced to the market. These advancements enable the creation of vaccines that offer longer-lasting protection, require fewer doses, and are suitable for a wider range of age groups. Additionally, innovations in vaccine delivery mechanisms, such as oral vaccines, contribute to increased vaccine acceptance and ease of administration, particularly in areas with limited healthcare infrastructure. The continuous evolution of vaccine technology not only enhances the overall effectiveness of cholera vaccines but also fuels market growth by providing healthcare providers and communities with better tools for disease prevention.

Cholera Vaccines Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, product and end user.

Breakup by Vaccine Type:

Whole Cell V. Cholerae O1 with Recombinant B-Subunit
Killed Oral O1 and O139

Whole cell V. cholerae O1 with recombinant B-subunit dominates the market

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes whole cell V. cholerae O1 with recombinant B-subunit and killed oral O1 and O139. According to the report, whole cell V. cholerae O1 with recombinant B-subunit represented the largest segment.

The whole cell V. cholerae O1 with recombinant B-subunit segment is propelled by the comprehensive protection offered by whole-cell vaccines against cholera caused by V. cholerae O1. The inclusion of recombinant B-subunit enhances immunogenicity, bolstering the vaccine's efficacy in inducing protective immune responses. Additionally, the rising global awareness about cholera's impact on public health underscores the importance of advanced vaccines. Moreover, governmental initiatives and collaborations with international health organizations amplify the distribution and administration of these vaccines, especially in endemic regions. In line with this, ongoing research and development efforts continually refine vaccine formulations, ensuring optimal safety and effectiveness. Apart from this, the evolving landscape of international travel and trade heightens the demand for robust preventive measures, boosting the adoption of this segment.

Breakup by Product:

Dukoral
Shanchol
Vaxchora
Euvichol and Euvichol-Plus
Others

Dukoral dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes dukoral, shanchol, vaxchora, euvichol and euvichol-plus, and others. According to the report, dukoral represented the largest segment.

The dukoral segment is propelled by the surging awareness regarding the unique formulation of the product, encompassing both cholera and ETEC (enterotoxigenic Escherichia coli) antigens. Additionally, its established reputation for safety and efficacy, backed by rigorous clinical trials, instills confidence among healthcare professionals and recipients alike, boosting its adoption. Moreover, the expanding travel and tourism sector drives demand for dukoral, as it addresses the risk of cholera and ETEC infections associated with global mobility. Furthermore, its oral administration aligns with the preference for non-invasive vaccination methods, especially in regions with limited healthcare infrastructure. In line with this, ongoing research to refine dukoral's formulation and increase accessibility in underserved areas underscores its significance, solidifying its position as a driver in the market's growth trajectory.

Breakup by End User:

Hospitals and Clinics
Research and Academic Laboratories
Others

Hospitals and clinics dominate the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, research and academic laboratories, and others. According to the report, hospitals and clinics represented the largest segment.

The hospitals and clinics segment dominates the market due to the increasing demand for quality healthcare services and medical interventions. Hospitals and clinics serve as primary access points for medical care, catering to a wide range of medical needs from routine check-ups to specialized treatments. Additionally, advancements in medical technology and treatments drive the need for modern and well-equipped healthcare facilities. Patients seek out hospitals and clinics that offer cutting-edge diagnostic and treatment options, thus encouraging the growth of this segment. Moreover, the growing aging population contributes significantly to the demand for healthcare services. As elderly individuals require more frequent medical attention, hospitals and clinics play a crucial role in providing geriatric care. Furthermore, the rise in chronic diseases necessitates ongoing medical care and management, prompting a greater reliance on hospitals and clinics for continuous patient support.

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The North American cholera vaccines market is stimulated by a solid healthcare framework and an emphasis on disease prevention, with stringent public health policies and high awareness increasing demand. International travel and trade further necessitate vaccination. In Asia Pacific, rising cholera outbreaks, lack of sanitation, government efforts, population density, and tourism focus attention on vaccination. Europe's market is propelled by strong healthcare systems and proactive disease surveillance, while travel and trade accentuate the requirement for vaccination. Latin America's growth is due to uneven access to sanitation and government campaigns. In the Middle East and Africa, erratic sanitation infrastructure and recurring cholera outbreaks necessitate vaccines, with governmental and international efforts addressing waterborne diseases.

Competitive Landscape:
The competitive landscape within the market for cholera vaccine is characterized by a dynamic interplay of various factors that shape the positioning of key players. Market participants engage in a multitude of strategies to gain a competitive edge, including product innovation, strategic collaborations, geographical expansion, and mergers and acquisitions. The quest to capture larger market shares and establish brand prominence drives companies to invest in research and development, aiming to offer novel solutions that cater to evolving consumer needs. Furthermore, the emphasis on customer-centric approaches and effective marketing strategies is pivotal in differentiating brands in a crowded marketplace. Regulatory compliance and adherence to industry standards also contribute to the competitive dynamics. The competitive landscape is ever evolving, with players continuously adapting to market trends, customer preferences, and technological advancements to maintain their relevance and sustain growth in this competitive arena.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Astellas Pharma Inc.
Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
Emergent BioSolutions Inc.
Eubiologics Co. Ltd.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
PharmaChoice Canada Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Valneva SE

Recent Developments:
In June 2022, Sanofi unveiled the initiation of its first Digital Accelerator, a significant step that aligns with its aspiration to evolve into a top-tier digital healthcare company.

Key Questions Answered in This Report

1. What was the size of the global cholera vaccines market in 2023?
2. What is the expected growth rate of the global cholera vaccines market during 2024-2032?
3. What are the key factors driving the global cholera vaccines market?
4. What has been the impact of COVID-19 on the global cholera vaccines market?
5. What is the breakup of the global cholera vaccines market based on the vaccine type?
6. What is the breakup of the global cholera vaccines market based on the product?
7. What is the breakup of the global cholera vaccines market based on the end user?
8. What are the key regions in the global cholera vaccines market?
9. Who are the key players/companies in the global cholera vaccines market?